Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Yoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 108.7K citations

Natural Sciences, Biostatistics, A/b Testing +13

Statistical significance for genomewide studies

John D. Storey, Robert Tibshirani · Proceedings of the National Academy of Sciences · 2003 · 10.1K citations · Full text

Life Sciences, Biostatistics, Genetics +13

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling, Paul Aisen, Laurel Beckett et al. · Alzheimer s & Dementia · 2011 · 7.1K citations · Full text

Medicine, Neurology, Neuroscience +17

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Leslie M. Shaw, Hugo Vanderstichele, Małgorzata Knapik-Czajka et al. · Annals of Neurology · 2009 · 2.1K citations · Full text

Medicine, Neurology, Neuroscience +17

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Frank Hulstaert, Kaj Blennow, Adrian Ivanoiu et al. · Neurology · 1999 · 732 citations · Full text

Veterinary Medicine, Immunology, Pathobiology +17